The High-Yield Waiting Game: Why I’m Continuing to Bet on FBIOP Over FBIO Right Now

We all know the Fortress Biotech (FBIO) story - a complex "hub and spoke" model that’s a constant battle between high-potential pipeline catalysts and the reality of a tight cash runway. But lately, I’ve been looking at the capital structure from a different angle. While most of the noise is around the common stock, the real play might be hiding in the **FBIOP** preferred shares. Here is my current thesis, laid out as logically as possible. # The Math vs. The Reality If you look at the SOFR (Secured Overnight Financing Rate) today - sitting around **3.69% -** a security yielding **9.375%** should theoretically be trading at a massive premium. Even if you tack on a generous **5% risk premium**, the math suggests a fair value of roughly **$26.75**. Instead, we’re seeing FBIOP trade in the **$12.25 range**. That’s a 50% discount to par. # The Elephant in the Room: The Dividend Pause Let’s be direct: Fortress paused the monthly cash dividend in July 2024. In most cases, a dividend cut is a "run for the hills" signal. But FBIOP is **cumulative**. Those payments aren’t gone; they are just stacking up in the back office. * Right now, the "arrears" (the back-pay owed to shareholders) is roughly **$3.70 per share**. * As an investor, you’re essentially buying a claim on future cash at a deep discount. # Why the Preferreds (FBIOP) Beat the Common (FBIO) Right Now I’m starting to see a shift in market action that suggests the "smart money" is leaning toward the preferreds, and for a few logical reasons: 1. **The "Priority" Gatekeeper:** Fortress cannot pay a single cent to common shareholders (FBIO) or buy back common stock until every penny of that $3.70 (and counting) in accrued dividends is paid to FBIOP holders. You are effectively the gatekeeper of their capital return policy. 2. **A Floor vs. A Ceiling:** The common stock is prone to dilution to fund the "spoke" companies. The preferreds, however, have a fixed par value of **$25.00**. Buying at $12 gives you a clear path to a 100% gain if the company simply stabilizes and resumes its obligations. 3. **Recent Momentum:** We’ve seen the price crawl up from the $4 lows of last year to over $12 today. This tells me the market is starting to price in a higher probability of a "rebound event"- likely driven by the recent FDA wins in the broader Fortress portfolio and specifically the PRV monetization. # Final Thoughts I don't have a crystal ball, and in biotech, "guaranteed" is a dangerous word. But looking at the structural protections of a cumulative preferred vs. the dilution risk of the common, the risk-reward for FBIOP at these levels feels severely discounted. The market is starting to wake up to the fact that you’re buying a $25 claim for $12, with a side order of $3.70 in back-pay. In a world where we’re constantly chasing 2x or 3x clinical moonshots, sometimes the best play is just sitting at the front of the line for when the cash starts flowing again.